ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,602.24
0.98%
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs Yen
158.1065
0.09%
Brent Oil
84.555
-0.17%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Xenon Pharmaceuticals Inc (XENE)

  7. Xenon Pharmaceuticals Inc (XENE) ニュース

XENE

Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:XENE
日付受信時刻ニュースソース見出しコード企業名
2024/06/1306 : 32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0606 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0606 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0606 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0606 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0606 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0605 : 22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0605 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
2024/06/0605 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/2821 : 30GlobeNewswire Inc.Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/1005 : 35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/1005 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/1005 : 01GlobeNewswire Inc.Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/0905 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/0805 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
2024/05/0305 : 01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
2024/04/1621 : 30GlobeNewswire Inc.Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
2024/04/0505 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/1305 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0908 : 47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0907 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0907 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0907 : 27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0809 : 04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0809 : 03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0606 : 01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0106 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
2024/03/0106 : 01GlobeNewswire Inc.Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
2024/02/2306 : 01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
2024/02/1423 : 12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XENEXenon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:XENE

最近閲覧した銘柄

CCOM
US100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MCD
McDonalds
NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
AMEX
XLE
Energy Select Sector SPDR
NYSE
DIS
Walt Disney
AMEX
SPY
SPDR S&P 500
FX
USDGBP
US Dollar vs Sterling
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有